{"id":83700,"date":"2020-04-18T11:32:16","date_gmt":"2020-04-18T14:32:16","guid":{"rendered":"https:\/\/megalabs.global\/eng\/?p=83700"},"modified":"2020-04-20T20:44:12","modified_gmt":"2020-04-20T23:44:12","slug":"se-descubre-nuevo-anticuerpo-contra-el-virus-sars-cov-2","status":"publish","type":"post","link":"https:\/\/megalabs.global\/eng\/se-descubre-nuevo-anticuerpo-contra-el-virus-sars-cov-2\/","title":{"rendered":"Se descubre nuevo anticuerpo contra el virus SARS-CoV-2"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;100&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; row_height_use_pixel=&#8221;&#8221;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; medium_width=&#8221;0&#8243; zoom_width=&#8221;0&#8243; zoom_height=&#8221;0&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text]En el per\u00edodo comprendido entre los a\u00f1os 2002-2003 tuvo lugar la epidemia con el virus SARS-CoV, que afect\u00f3 m\u00e1s de 17 pa\u00edses. Un sobreviviente de dicha epidemia fue qui\u00e9n aport\u00f3 la muestra biol\u00f3gica para que Ter Meulen y colaboradores encontraran el anticuerpo CR3022 en 2006. Este anticuerpo es capaz de unirse a la prote\u00edna de la envoltura de SARS-CoV llamada \u201cspike\u201d, por su aspecto de espina al ser observada a trav\u00e9s de microscop\u00eda electr\u00f3nica. Esta prote\u00edna es clave para que el virus pueda ingresar a la c\u00e9lula.<\/p>\n<p>La prote\u00edna spike de SARS-CoV y de SARS-CoV-2 comparten el 77% de la estructura primaria. Dicha similitud fue la que impuls\u00f3 a Tian X y colaboradores a analizar si el anticuerpo CR3022 tambi\u00e9n es capaz de unirse con buena afinidad a la prote\u00edna spike de SARS-CoV-2. Adem\u00e1s de confirmarlo, los autores establecieron la importancia del hallazgo, dado que algunos de los potentes anticuerpos que se han hallado para SARS-CoV han fallado en unirse a la prote\u00edna spike de SARS-CoV-2.<\/p>\n<p>Yuan y colaboradores recientemente analizaron la uni\u00f3n entre el virus y el anticuerpo con resoluci\u00f3n at\u00f3mica nuclear. Observaron que CR3022 no compite con el sitio de uni\u00f3n a la c\u00e9lula del receptor celular ACE2 (enzima convertidora de angiotensina I-2; como ocurre con otros anticuerpos), sino que act\u00faa por otro mecanismo. La prote\u00edna spike es capaz de estar en dos conformaciones, an\u00e1logamente como un \u201cswitch\u201d de una llave el\u00e9ctrica, puede estar \u201con\u201d y \u201coff\u201d. Spike solamente es capaz de unirse al receptor ACE2 si est\u00e1 en su conformaci\u00f3n \u201con\u201d y ocurre de igual forma con el anticuerpo CR3022. Cuando CR3022 se une a la prote\u00edna Spike, hace que \u00e9sta \u00faltima cambie de conformaci\u00f3n y pase a su estado \u201coff\u201d, impidiendo as\u00ed que se una con el receptor ACE2.<\/p>\n<p>Mediante estudios <em>in vitro<\/em> se observ\u00f3 que si bien CR3022 no neutraliza completamente a SARS-CoV-2, es capaz de colaborar en su tratamiento. Su utilizaci\u00f3n en una posible vacuna para SARS-CoV-2 requiere a\u00fan m\u00e1s an\u00e1lisis, pero estos hallazgos resultan alentadores para la comunidad cient\u00edfica.<\/p>\n<p><strong>Bibliograf\u00eda:<\/strong><br \/>\n&#8211; Yuan M et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science . 2020. eabb7269. Doi: 10.1126\/science.abb7269.<br \/>\n&#8211; Tian X et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emergin Microbes &amp; Infections. 2020. 9 (1). Doi: 10.1080\/22221751.2020.1729069[\/vc_column_text][\/vc_column][\/vc_row][vc_row unlock_row=&#8221;&#8221; row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;100&#8243; gutter_size=&#8221;3&#8243; column_width_use_pixel=&#8221;yes&#8221; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; row_height_use_pixel=&#8221;&#8221; column_width_pixel=&#8221;800&#8243;][vc_column width=&#8221;1\/1&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; border_color=&#8221;color-877404&#8243; border_style=&#8221;solid&#8221; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; css=&#8221;.vc_custom_1572995729128{border-top-width: 1px !important;border-bottom-width: 1px !important;padding-top: 18px !important;padding-bottom: 18px !important;}&#8221; el_class=&#8221;descarga-pdf&#8221; limit_content=&#8221;&#8221;][vc_column_inner width=&#8221;1\/1&#8243;][vc_icon position=&#8221;left&#8221; icon_image=&#8221;82110&#8243; icon_color=&#8221;color-877404&#8243; media_size=&#8221;42&#8243; text_font=&#8221;font-195522&#8243; text_weight=&#8221;700&#8243; linked_title=&#8221;yes&#8221; title=&#8221;Descargar Documento&#8221; link=&#8221;url:%2Fwp-content%2Fuploads%2F2020%2F04%2FConexion-Megalabs-Se-descubre-nuevo-anticuerpo-contra-el-virus-SARS-CoV-2.pdf|title:Conexion%20Megalabs%20-%20Se%20descubre%20nuevo%20anticuerpo%20contra%20el%20virus%20SARS-CoV-2|target:%20_blank|&#8221;]Conexion Megalabs &#8211; Se descubre nuevo anticuerpo contra el virus SARS-CoV-2[\/vc_icon][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/1&#8243;][vc_single_image media=&#8221;83703&#8243; media_width_use_pixel=&#8221;yes&#8221; alignment=&#8221;center&#8221; media_width_pixel=&#8221;700&#8243;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;100&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; row_height_use_pixel=&#8221;&#8221;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; medium_width=&#8221;0&#8243; zoom_width=&#8221;0&#8243; zoom_height=&#8221;0&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text]En el [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":83702,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[107],"tags":[],"class_list":["post-83700","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-estudios-preclinicos"],"_links":{"self":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/83700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/comments?post=83700"}],"version-history":[{"count":0,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/83700\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/media\/83702"}],"wp:attachment":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/media?parent=83700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/categories?post=83700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/tags?post=83700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}